Ra Capital Management, L.P. Dyne Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $4.82 Billion
- Q1 2025
A detailed history of Ra Capital Management, L.P. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 9,714,392 shares of DYN stock, worth $138 Million. This represents 2.11% of its overall portfolio holdings.
Number of Shares
9,714,392
Previous 6,381,144
52.24%
Holding current value
$138 Million
Previous $150 Million
32.41%
% of portfolio
2.11%
Previous 2.43%
Shares
5 transactions
Others Institutions Holding DYN
# of Institutions
216Shares Held
116MCall Options Held
322KPut Options Held
66.2K-
Janus Henderson Group PLC London, X010.4MShares$147 Million0.06% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$130 Million27.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.41MShares$105 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$105 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$77.7 Million13.81% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $737M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...